Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are indicated for improvement of glycemic control in adults with type 2 diabetes. Cost is one aspect of treatment to be considered, in addition to clinical benefits, when selecting optimal therapy for a patient. The objective of this stud...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clinicoecon Outcomes Res
Auteurs principaux: McDonell, Amanda L, Kiiskinen, Urpo, Zammit, Danielle C, Kotchie, Robert W, Thuresson, Per-Olof, Nicolay, Claudia, Haslam, Thomas, Bruinsma, Michiel, Janszen-Van Oosterhout, Anne-Jeanine, Otto, Thorsten
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2015
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4321412/
https://ncbi.nlm.nih.gov/pubmed/25674008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S69981
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires